Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163


Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 Mar 12. pii: S1474-4422(18)30069-3. doi: 10.1016/S1474-4422(18)30069-3. [Epub ahead of print]


Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.

Vistbakka J, Sumelahti ML, Lehtimäki T, Elovaara I, Hagman S.

Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921. [Epub ahead of print]


Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.


JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.

Basnyat P, Virtanen E, Elovaara I, Hagman S, Auvinen E.

J Neurovirol. 2017 Oct;23(5):734-741. doi: 10.1007/s13365-017-0560-x. Epub 2017 Aug 22.


Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.


Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.


Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.


Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.


The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.


Circulating microRNAs as biomarkers in progressive multiple sclerosis.

Vistbakka J, Elovaara I, Lehtimäki T, Hagman S.

Mult Scler. 2017 Mar;23(3):403-412. doi: 10.1177/1352458516651141. Epub 2016 Jul 11.


Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.

Kuusisto H, Vahvelainen T, Hämäläinen P, Luukkaala T, Elovaara I.

J Neurol Sci. 2016 Jun 15;365:50-3. doi: 10.1016/j.jns.2016.03.046. Epub 2016 Apr 3.


Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.


Adipsin Is Associated with Multiple Sclerosis: A Follow-Up Study of Adipokines.

Natarajan R, Hagman S, Hämälainen M, Leppänen T, Dastidar P, Moilanen E, Elovaara I.

Mult Scler Int. 2015;2015:371734. doi: 10.1155/2015/371734. Epub 2015 Nov 8.


[Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].

Elovaara I, Soilu-Hänninen M, Kuusisto H, Martola J, Tienari P, Färkkilä M, Remes AM.

Duodecim. 2015;131(17):1571-80. Review. Finnish.


Three-decade neurological and neurocognitive follow-up of HIV-1-infected patients on best-available antiretroviral therapy in Finland.

Heikinheimo T, Poutiainen E, Salonen O, Elovaara I, Ristola M.

BMJ Open. 2015 Nov 5;5(11):e007986. doi: 10.1136/bmjopen-2015-007986.


Anti-JC virus seroprevalence in a Finnish MS cohort.

Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I.

Acta Neurol Scand. 2016 May;133(5):391-7. doi: 10.1111/ane.12475. Epub 2015 Sep 8.


Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.

Basnyat P, Hagman S, Kolasa M, Koivisto K, Verkkoniemi-Ahola A, Airas L, Elovaara I.

Mult Scler Relat Disord. 2015 Jul;4(4):334-8. doi: 10.1016/j.msard.2015.06.008. Epub 2015 Jun 17.


Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.

Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Review.


Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis.

Hagman S, Kolasa M, Basnyat P, Helminen M, Kähönen M, Dastidar P, Lehtimäki T, Elovaara I.

J Neuroimmunol. 2015 Mar 15;280:43-8. doi: 10.1016/j.jneuroim.2015.02.006. Epub 2015 Feb 25.


Longitudinal assessment of clinically isolated syndrome with diffusion tensor imaging and volumetric MRI.

Kolasa M, Hakulinen U, Helminen M, Hagman S, Raunio M, Rossi M, Brander A, Dastidar P, Elovaara I.

Clin Imaging. 2015 Mar-Apr;39(2):207-12. doi: 10.1016/j.clinimag.2014.10.014. Epub 2014 Oct 23.


Supplemental Content

Loading ...
Support Center